Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) Shares Shorted: Short Interest Down 87.1% in September
by Tristan Rich · The Markets DailyChemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB – Get Free Report) was the recipient of a large decline in short interest during the month of September. As of September 30th, there was short interest totaling 10,544 shares, a decline of 87.1% from the September 15th total of 81,947 shares. Based on an average daily trading volume, of 215,472 shares, the short-interest ratio is currently 0.0 days. Approximately 0.2% of the company’s shares are sold short.
Chemomab Therapeutics Stock Performance
Shares of NASDAQ CMMB traded up $0.01 during midday trading on Monday, reaching $1.39. The stock had a trading volume of 17,208 shares, compared to its average volume of 98,844. The company’s 50 day moving average price is $2.13 and its 200 day moving average price is $1.84. Chemomab Therapeutics has a twelve month low of $1.05 and a twelve month high of $3.50. The firm has a market cap of $10.08 million, a price-to-earnings ratio of -0.65 and a beta of 0.74.
Chemomab Therapeutics (NASDAQ:CMMB – Get Free Report) last posted its quarterly earnings data on Thursday, August 20th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.12).
Analysts Set New Price Targets
Several equities research analysts have recently weighed in on CMMB shares. Weiss Ratings raised Chemomab Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, September 16th. Wall Street Zen raised Chemomab Therapeutics to a “hold” rating in a research note on Saturday, October 3rd. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Reduce”.
Get Our Latest Research Report on CMMB
Institutional Trading of Chemomab Therapeutics
An institutional investor recently raised its stake in Chemomab Therapeutics stock. Kestra Private Wealth Services LLC grew its holdings in shares of Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB – Free Report) by 19.3% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 61,710 shares of the company’s stock after acquiring an additional 10,000 shares during the period. Kestra Private Wealth Services LLC owned 0.86% of Chemomab Therapeutics worth $97,000 as of its most recent SEC filing. 46.05% of the stock is owned by hedge funds and other institutional investors.
Chemomab Therapeutics Company Profile
Chemomab Therapeutics Ltd. is a clinical-stage biotechnology company focused on developing therapies for chronic inflammatory and fibrotic diseases. The company’s research is centered on CCL24, a chemokine believed to contribute to inflammation, fibrosis and tissue damage across several disease areas.
Chemomab’s lead product candidate is CM-101, a proprietary monoclonal antibody designed to block CCL24 activity. The therapy has been evaluated in clinical studies for conditions including primary sclerosing cholangitis, a progressive liver disease, and systemic sclerosis, an autoimmune disorder that can cause widespread fibrosis.